Survival benefits of PARP inhibitors in advanced breast cancer: a mirage?

Ann Oncol. 2020 Nov;31(11):1432-1434. doi: 10.1016/j.annonc.2020.09.018. Epub 2020 Sep 29.

Authors

T Grinda¹, S Delaloge²

Affiliations

¹ Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
² Department of Cancer Medicine, Gustave Roussy, Villejuif, France; Inserm U931, Cancer Biomarkers, Paris Saclay University, Gustave Roussy, Villejuif, France. Electronic address: [email protected].

PMID: 33007379
DOI: 10.1016/j.annonc.2020.09.018

No abstract available

Publication types

Editorial
Comment

MeSH terms

BRCA1 Protein
Breast Neoplasms* / drug therapy
Breast Neoplasms* / genetics
Germ Cells
Humans
Phthalazines / therapeutic use
Poly(ADP-ribose) Polymerase Inhibitors* / therapeutic use

Substances

BRCA1 Protein
BRCA1 protein, human
Phthalazines
Poly(ADP-ribose) Polymerase Inhibitors
talazoparib